Premature Birth

37

Pipeline Programs↗

1

Active Trials↗

20

Companies Involved↗

Premature Birth is a moderately active landscape with 37 programs across 20 companies. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Johnson & Johnson, Roche. 30 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

57/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Johnson & Johnson

1 program

Roche

1 program

Kaken Pharmaceutical

1 program

Sanofi

1 program

GSK

1 program

Pipeline

Programs by Phase

Preclinical1

Ferrous Sulfate

Auerbach Hematology Oncology Associates P C

Phase 1

No programs

Phase 22

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Domperidone

Johnson & Johnson

Phase 34

Epoetin Beta

Roche

Caffeine Citrate

Kaken Pharmaceutical

Atosiban

GSK

N-Acetylcysteine

Novartis

Approved30

Fluconazole

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Nifedipine

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Methadone

Hikma Pharmaceuticals LLC

Lactulose

Solvay Pharmaceuticals

Ibuprofen

Kenvue Brands

Analysis

Trial Status

9

clinical trials

Completed4 · 44%

Terminated3 · 33%

Unknown status1 · 11%

Recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Effect of the Infant Behavioral Assessment and Intervention Program (IBAIP) in Preterm Infants on Neurodevelopment at 2 Years Corrected Age

Recruiting·UUniversity Hospital, Brest·Preclinical·NCT04685356·240 enrolled

Cervical Pessary vs. Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies

Completed·VVietnam National University·N/A·NCT02623881·300 enrolled

Role of Probiotic Use in Outcomes of Premature Birth

Completed·UUniversity of Health Sciences Lahore·N/A·NCT05710575·100 enrolled

Group Antenatal Care: Effectiveness for Maternal/Infant and HIV Prevention Outcomes and Contextual Factors Linked to Implementation Success in Malawi

Completed·UUniversity of Illinois at Chicago·Preclinical·NCT03673709·1,887 enrolled

Heated Humidified High-Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure as Primary Respiratory Support in Preterm Infants With Respiratory Distress Syndrome: A Randomized Controlled Trial

Completed·KKayseri City Hospital·Preclinical·NCT07693530·86 enrolled

Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity

Terminated·OOswaldo Cruz Foundation·Phase 3·NCT00303082·645 enrolled

Correction of Neonatal Glutathione by N-acetylcysteine in Pregnant Women at Risk of Premature Birth (GSH MAP)

Terminated·NNantes University Hospital·Phase 2/3·NCT03596125·39 enrolled

Antenatal Rescue Course of Glucocorticoids in Threatened Premature Birth

Terminated·UUniversity of Oulu·Phase 4·NCT00295464·440 enrolled

Prediction and Prevention of Twin Premature Birth 2021

Unknown status·—·Phase 4·NCT05061641·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)